BCBSAZ launches pilot program for monoclonal antibody treatment
BCBSAZ is piloting a monoclonal antibody (mAb) treatment referral program for high-risk members who have tested positive for COVID-19 and have mild to moderate symptoms. Monoclonal antibody treatment (for high-risk individuals ages 12 years and older) has received emergency use authorization from the FDA because it is proving to be effective in reducing severe COVID-19 illness and preventing hospitalization and death in the high-risk population. Our goal is to eventually make this treatment available to more Arizonans and to minimize the impact on hospitals from any future COVID-19 surges.
For more information about our pilot program, see our November 2 provider notice and access our provider FAQs. If you have patients who have tested positive for COVID-19 and have mild to moderate symptoms, you can check availability for mAb treatment through the Arizona Poison Control Systems COVID-19 Hotline (1-844-542-8201) or use the online HSS federal locator search tool. For more information, see the NIH guidance for therapeutic management of non-hospitalized individuals.
BCBSAZ launches monoclonal antibody program (11/02/21)
Provider FAQs (11/02/21)
Supporting our community
Some examples of how we’ve partnered with state and local leaders include:
• Helping to facilitate testing
• Offering funding for needed supplies
• Contributing to food banks and other community resources to support essential services
• Assisting state leadership in creating multiple, highly efficient COVID-19 vaccination clinic sites
Mitigating exposure through virtual services
Virtual services have become an important part of a coordinated response to the coronavirus pandemic. BCBSAZ has expanded this coverage and in many cases is waiving member cost share.
Tele-everything – BCBSAZ Quick Reference Guide (03/05/21)